YU22401A - Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom - Google Patents

Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom

Info

Publication number
YU22401A
YU22401A YU22401A YU22401A YU22401A YU 22401 A YU22401 A YU 22401A YU 22401 A YU22401 A YU 22401A YU 22401 A YU22401 A YU 22401A YU 22401 A YU22401 A YU 22401A
Authority
YU
Yugoslavia
Prior art keywords
combination
capecytabine
acetyldynaline
cisplatinium
gemcytabine
Prior art date
Application number
YU22401A
Other languages
English (en)
Inventor
William Richard Grove
Wayne Daniel Klohs
Ronald Lynn Merriman
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU22401A publication Critical patent/YU22401A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Acetildinalin, u kombinaciji sa gemcitabinom, njegovom farmaceutski prihvatljivom solju, capecitabinom ili cisplatinom, je sinergična kombinacija agenasa koja se koristi za dobijanje leka za kancer
YU22401A 1998-09-25 1999-07-08 Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom YU22401A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
YU22401A true YU22401A (sh) 2004-03-12

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
YU22401A YU22401A (sh) 1998-09-25 1999-07-08 Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom

Country Status (34)

Country Link
US (3) US6469058B1 (sh)
EP (1) EP1115391B1 (sh)
JP (1) JP2002525320A (sh)
KR (1) KR20010075348A (sh)
CN (1) CN1319009A (sh)
AP (1) AP2001002109A0 (sh)
AT (1) ATE225655T1 (sh)
AU (1) AU762079B2 (sh)
BG (1) BG105470A (sh)
BR (1) BR9913952A (sh)
CA (1) CA2342981A1 (sh)
CZ (1) CZ2001905A3 (sh)
DE (1) DE69903458T2 (sh)
DK (1) DK1115391T3 (sh)
EA (1) EA200100369A1 (sh)
EE (1) EE200100187A (sh)
ES (1) ES2185378T3 (sh)
GE (1) GEP20043199B (sh)
HK (1) HK1040190A1 (sh)
HR (1) HRP20010225B1 (sh)
HU (1) HUP0103640A3 (sh)
ID (1) ID30046A (sh)
IL (1) IL141951A0 (sh)
IS (1) IS5888A (sh)
NO (1) NO20011493L (sh)
NZ (1) NZ510504A (sh)
OA (1) OA11659A (sh)
PL (1) PL348673A1 (sh)
PT (1) PT1115391E (sh)
SK (1) SK3602001A3 (sh)
TR (1) TR200100859T2 (sh)
WO (1) WO2000018393A1 (sh)
YU (1) YU22401A (sh)
ZA (1) ZA200102233B (sh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CA2482508A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
ATE507879T1 (de) 2005-07-22 2011-05-15 Tomotherapy Inc System zur verabreichung einer strahlentherapie auf ein sich bewegendes zielgebiet
CA2616292A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treament plan
EP1907981A4 (en) * 2005-07-22 2009-10-21 Tomotherapy Inc METHOD AND SYSTEM FOR DOSE EVALUATION ADMINISTERED
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
JP2009502251A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 放射線治療システムによって送達された線量を評価するシステム及び方法
JP2009502253A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 関心の移動領域に対して放射線療法を施すシステムおよび方法
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
CN101534852B (zh) * 2006-08-31 2013-02-13 光谱医药公司 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
JO3197B1 (ar) 2009-04-06 2018-03-08 Otsuka Pharma Co Ltd (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
CN107469240B (zh) 2013-02-26 2020-04-21 安科锐公司 多叶准直器和用于准直治疗放射束的系统
US10189797B2 (en) * 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

Also Published As

Publication number Publication date
US6469058B1 (en) 2002-10-22
PT1115391E (pt) 2003-02-28
AU762079B2 (en) 2003-06-19
CA2342981A1 (en) 2000-04-06
TR200100859T2 (tr) 2001-08-21
DK1115391T3 (da) 2003-02-10
WO2000018393A1 (en) 2000-04-06
IS5888A (is) 2001-03-14
ZA200102233B (en) 2002-06-18
NO20011493D0 (no) 2001-03-23
NO20011493L (no) 2001-05-23
HRP20010225A2 (en) 2002-04-30
ES2185378T3 (es) 2003-04-16
JP2002525320A (ja) 2002-08-13
HK1040190A1 (zh) 2002-05-31
EA200100369A1 (ru) 2001-10-22
AU5092199A (en) 2000-04-17
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
DE69903458D1 (de) 2002-11-14
ATE225655T1 (de) 2002-10-15
CZ2001905A3 (cs) 2001-08-15
CN1319009A (zh) 2001-10-24
DE69903458T2 (de) 2003-07-10
ID30046A (id) 2001-11-01
AP2001002109A0 (en) 2001-03-31
US20030086965A1 (en) 2003-05-08
HRP20010225B1 (en) 2004-10-31
EE200100187A (et) 2002-08-15
PL348673A1 (en) 2002-06-03
KR20010075348A (ko) 2001-08-09
NZ510504A (en) 2003-09-26
GEP20043199B (en) 2004-03-25
SK3602001A3 (en) 2002-07-02
BG105470A (en) 2001-12-29
OA11659A (en) 2004-12-08
US20030170300A1 (en) 2003-09-11
BR9913952A (pt) 2001-06-12
EP1115391B1 (en) 2002-10-09
HUP0103640A2 (en) 2002-06-29
EP1115391A1 (en) 2001-07-18

Similar Documents

Publication Publication Date Title
YU22401A (sh) Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
CY1108918T1 (el) Φαρμακευτικοι συνδυασμοι οξυκωδονης και ναλοξονης
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
SE9704870D0 (sv) New pharmaceutical formulation I
PT929516E (pt) Derivados da benzamidina e sua utilizacao em composicoes farmaceuticas com efeito antagonista da ltb4
BR9604951A (pt) Composição farmacêutica contendo derivados den n-fosfonoglicina par inibir o desenvolvimento de viroses e cânceres
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
DK0902789T3 (da) Androstenderivater
SE9900961D0 (sv) Novel compounds
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
PT1105006E (pt) Incorporacao de agentes de modificacao do fumo em barras de material para fumar
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
BR9809571A (pt) Composição medicinal e processo para produzì-la
PT1242410E (pt) Compostos novos
DK1330244T3 (da) Præparater der omfatter modafinilforbindelser
NO20000462D0 (no) 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid derivater, deres fremstilling og deres anvendelse i terapi
SE9802209D0 (sv) Novel compounds
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
ES2166816T3 (es) Derivados piridil-imidazolicos y procedimientos para su preparacion.
PT1058544E (pt) Inibicao da actividade do tnf
DK1227826T3 (da) Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf
IT1291895B1 (it) Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo